Compare Boston Scientific Corporation (BSX) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ING Groep NV — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while ING Groep NV trades at $32.76 (market cap $93.58B). The key difference: ING Groep NV is the larger of the two by market cap, and ING Groep NV pays a 3.86% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ING | |
|---|---|---|
Market Cap | $66.37B | $93.58B |
Sector | Health | Financials |
52-Week High | $108.14 | $32.96 |
52-Week Low | $42.63 | $22.45 |
Enterprise Value | $75.94B | — |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ING trades at $32.30, down 0.28% on the day, with strong analyst support (62.5% buy ratings) and bullish technical signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.63 exceeding the $0.60 forecast. Revenue growth remains steady at $22.9B for 2025, while net income margin stands at 27.84%. Recent corporate developments include a new global subscription banking model and management board appointments.
The outlook remains positive given ING's earnings momentum, attractive valuation (P/E 12.95), and strategic initiatives. Key risks include negative operating cash flow trends and exposure to European banking sector volatility. With intrinsic value estimates around $34 from DCF analyses, the stock offers potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
